PCM
PRCT icon

Portolan Capital Management’s Procept Biorobotics PRCT Stock Holding History

Portolan Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.13M Sell
227,010
-24,706
-10% -$619K 0.19% 115
2026
Q1 		$6.3M Sell
251,716
-3,402
-1% -$95.9K 0.34% 84
2025
Q4 		$8.03M Buy
+255,118
New +$8.46M 0.43% 80

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Portolan Capital Management's PRCT Position: Q2 2026 in Review

Portolan Capital Management reduced its Procept Biorobotics (PRCT) stake by 9.8% in Q2 2026, selling an estimated $619K and leaving 227,010 shares worth $5.13M. The position accounts for 0.19% of the portfolio, ranked #115.

Portolan Capital Management first reported a position in PRCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.03M in Q4 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Portolan Capital Management held 227,010 shares of Procept Biorobotics worth $5.13M as of Q2 2026.
  • Portolan Capital Management sold 24,706 Procept Biorobotics shares in Q2 2026, an estimated $619K.
  • Procept Biorobotics made up 0.19% of Portolan Capital Management's portfolio in Q2 2026, its #115 holding.
  • Portolan Capital Management first reported a position in Procept Biorobotics in Q4 2025 and has held it in 3 quarters since.
  • Portolan Capital Management's Procept Biorobotics position peaked at $8.03M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Portolan Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.